English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCoping with grief and holiday sadness; “biological age” as a tool to predict early colorectal cancer, genetic mutations accumulate in smokers with MDS, two clinical trials show promise for an antibody to treat high-risk form of lymphoma, and more.
Tag: Multiple Myeloma
Filling Out the Roadmap for Faster Drug Approvals
A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.
Research shows new treatment could delay cancer progression in patients with high-risk smoldering multiple myeloma
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.
EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting
Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).
Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
Fred Hutch at ASH: Plenary session on socioeconomic barriers to transplant, new leukemia treatments and phasing out ‘cumbersome’ urine test
The of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme of many presentations by Fred Hutch Cancer Center experts, including: Meta-analyses show socioeconomic factors limit access to transplants and clinical trials, highlighting strategies to overcome barriers.
Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple Myeloma
A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the disease, a new study led by Roswell Park Chief of Clinical Genomics Kenan Onel, MD, PhD, reveals.
MD Anderson Research Highlights for September 4, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Phase 1 BAFF CAR T clinical trial for patients with relapsed and refractory multiple myeloma underway at UH Seidman Cancer Center
University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial. He says in the two years since the foundational pre-clinical work was completed, the team has shown that it’s feasible to manufacture BAFF CAR T-cells for human subjects.
Tip Sheet: Summer science education, new chief nursing officer, DEI program updates — and a new endpoint for multiple myeloma
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Quadruple Therapies and the Future of Multiple Myeloma Treatment
ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
Recent FDA Committee Vote Could Speed Multiple Myeloma Drug Approval
An FDA committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease, when evaluating proposed drugs to treat multiple myeloma. The 12-0 vote was based primarily on an analysis spearheaded by C. Ola Landgren, M.D., Ph.D., first author of a new paper published May 20 in the journal Blood.
Firefighter, a cancer survivor, discovers and embraces Sylvester’s large community of research and support
Naples (FL) firefighter, David Perez, initially kept his cancer diagnosis quiet, but now speaks out about the importance of fire fighter health and cancer in the fire service. “My eyes really opened up as to how many firefighters have been diagnosed with cancer and how many people there [Sylvester’s Firefighter Cancer Initiative] are fighting for us,” Perez said.
New study points to racial and social barriers that block treatment for multiple myeloma
Socioeconomic factors are preventing some patients from accessing common treatment to stop progression of multiple myeloma.
FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies
An FDA advisory committee (ODAC) voted 12-0 today in favor of a major shift in how the agency evaluates new treatments for multiple myeloma. If approved by the FDA, the result will be faster approval of new treatments for multiple myeloma.
MD Anderson Research Highlights for February 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.
Moffitt Develops First Individualized Predictive Model for Multiple Myeloma Treatment
In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers in collaboration with Sylvester Comprehensive Cancer Center and groups around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies.
RESEARCH ALERT: Stopping Multiple Myeloma
Cedars-Sinai Cancer investigators have discovered a protein expressed on multiple myeloma cancer cells that drives disease growth and development. The new study found that blocking part of the protein’s unique signaling pathway stops myeloma growth in culture and in laboratory mice.
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.
Sylvester researchers help identify mechanisms by which multiple myeloma escapes targeted immunotherapy
Researchers at Sylvester Comprehensive Cancer Center are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant to initially effective T-cell therapies. Article in Aug. 31 issue of Nature Medicine.
Ola Landgren, MD, PhD, Multiple Myeloma researcher at Sylvester Comprehensive Cancer Center is available for interviews.
MULTIPLE MYELOMA EXPERT: If you are seeking an expert to discuss Multiple Myeloma, its causes, treatment options and the latest research, Ola Landgren, M.D., Ph.D., is available today. Dr. Landgren is Chief of the Division of Myeloma at Sylvester Comprehensive…
MD Anderson Research Highlights for July 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Roswell Park Study is First to Show That Exercise Strengthens Immune System in Multiple Myeloma Patients
Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.
IU cancer center researcher leads first in-human multiple myeloma study with 90.5 percent response rate
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5 percent overall response rate.
Scientists discover new lead in hunt for myeloma drug
A molecule involved in fat transport and metabolism is key to the progression of the malignant blood cancer multiple myeloma, researchers report today in eLife.
Triple-drug therapy for post-transplant management of multiple myeloma
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
Novel Drug Shows Early Promise in Treating Multiple Myeloma
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania’s Abramson Cancer Center at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 565).
Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
Cancer Expert Shares Troubling Research on World Trade Center Exposure
Police officers and construction workers who responded on September 11, 2001, to the World Trade Center disaster in New York City and worked in its aftermath had at least twice the risk of developing the precursor for multiple myeloma compared…
Ochsner Health expert available to comment on Multiple Myeloma
Ochsner Health hematologist oncologist, Dr. Andy Dalovisio is available to comment on Multiple Myeloma and other forms of blood cancer.
JMIR Formative Research | Digital Life Coaching During Stem Cell Transplantation
JMIR Publications recently published “Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study” in JMIR Formative Research which reported that the authors launched a single-arm pilot study to investigate the feasibility of patient engagement with digital life coaching (DLC) during this intensive period.
Researchers find link between genetic mutations and cancer treatment resistance
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
Stanford cancer team halts growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3
Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
MD Anderson Research Highlights for September 22, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.
Moffitt Cancer Center Joins Dana-Farber Cancer Institute to Help Stop Blood Cancer
Moffitt Cancer Center has joined Dana-Farber Cancer Institute to provide free screenings to eligible adults who are at a higher risk for having or developing multiple myeloma or other related conditions. This initiative is through the PROMISE Study, a national cancer screening/cohort program to help researchers understand who is at risk based on a number of factors. The goal is to detect multiple myeloma before it becomes symptomatic and to monitor those who are at increased risk in order to study and hopefully prevent the development of the disease.
Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
Mayo Clinic researchers study new class of drugs to treat multiple myeloma
Mayo Clinic researchers are studying a new class of immunotherapy drugs called “bispecific antibodies” that have demonstrated potent tumor-killing activity in multiple myeloma. A paper highlighting this work was published in Blood Cancer Discovery.
UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell Therapy
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
The University of Kansas Cancer Center Among the First to Offer CAR T-cell Therapy to Treat Multiple Myeloma
The University of Kansas Cancer Center is the first and only site in the region to offer CAR T-cell therapy to treat multiple myeloma, a type of blood cancer that affects about 30,000 people each year.
Multiple Myeloma Explained
Expert from Rutgers Cancer Institute of New Jersey shares information on symptoms, treatment and more to highlight multiple myeloma awareness month.
Lack of diversity in genomic databases may affect therapy selection for minority groups
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
The researchers investigated the use of genomic databases and found that tumor mutation burden was significantly inflated in Black patients compared to White patients.
As a result of the study, clinicians who are using public genomic databases need to be aware of the potential for inflated tumor mutation burden values and how that may affect therapy selection and outcomes, especially for patients from underrepresented groups.
CAR T-cell therapy generates lasting remissions in patients with multiple myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
New recommendations aim to eliminate racial bias in myeloma trials
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
Off-the-Shelf Immune Drug Shows Promise in Aggressive Multiple Myeloma
A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma.
Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.
Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App